Salesforce, Inc. (CRM.NYSE) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates when the seat question is answered with data rather than rhetoric. Two consecutive quarters of accelerating organic subscription growth, disclosed consumption revenue and stable net revenue retention would turn Agentforce from a bundling suspicion into a monetisation engine. Continued float reduction then amplifies the effect: rising cash earnings meet an expanding multiple as growth investors return to a name they abandoned. A priced Anthropic listing validates the partnership. Outcome: re-rating toward mid-teens cash earnings and materially higher returns.

The bear case activates if the FY28 renewal cohort shows seat contraction while the buyback pulse fades after October 2026 settlement. Organic growth slips below 6%, cRPO growth converges down to reported revenue, and the Anthropic mark reverses — removing the accounting flattery that made trailing earnings look cheap. Management responds with a large debt-funded acquisition at 5% coupons, deferring repurchases and reviving integration-complexity concerns. The result is a permanently lower multiple on genuinely stagnant per-share cash flow.

The settled belief is that Salesforce is the AI era's roadkill: a seat-based incumbent whose own agents eat its licences. The stock was down 22% year-to-date before the August print and returned +2.5% over twelve months against +20.8% for the S&P 500 [3][18]. Sell-side keeps $269 medians while the tape pays roughly 10x cash earnings, treating the FY30 $63bn target as promotional [4][18].

The crowd underestimates these shares, but not for the reason bulls give. The overlooked evidence is arithmetic, not narrative: $15.15bn of TTM free cash flow against a $195bn capitalisation is a 7.8% yield, and management is returning 190% of it while retiring 14%+ of the float [1][5]. Even with organic growth stuck near 7%, per-share cash flow compounds at a double-digit rate. The market is pricing terminal decline where the evidence supports terminal maturity — a different, and far cheaper, mistake.

Recognition hinges on the FY28 renewal cohort: two quarters of stable net revenue retention in Agentforce accounts would falsify the cannibalisation thesis empirically. Watch for cRPO growth holding above reported revenue growth through 2027; the first repricing sign is multiple expansion on in-line, not beat, quarters.